| UHC UMR Medical and Drug | Uplizna® (Inebilizumab-Cdon) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Upper Extremity Prosthetic Devices – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Vertebral Body Tethering for Scoliosis – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Erythropoiesis-Stimulating Agents – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Evkeeza® (Evinacumab-Dgnb) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Gender Dysphoria Treatment – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Home Traction Therapy – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Leqembi® (Lecanemab-Irmb) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Oncology Medication Clinical Coverage – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Repository Corticotropin Injections – Commercial Medical Benefit Drug Policy | 2026-04-01 |